A New Vision for Precision Medicine
Our team is dedicated to pioneering precision medicine in inflammatory disease by harnessing the power of single-cell RNA sequencing and human disease biology at scale.
Mission & Vision
Celsius is a New Way of Seeing
We’ve taken a new approach to understand human disease biology through a powerful combination of single-cell genomics and machine learning.
Celsius is Developing Precision Therapies for Complex, Multifactorial Diseases
The promise of precision medicine has yet to benefit immuno-inflammatory diseases. Now, with new insights, we can build a broad therapeutics pipeline, identify targeted patient populations and design smarter clinical studies in these complex conditions.
Collaboration is at the Core of all We Do
Collaboration is a fundamental tenet of our ecosystem. Our multidisciplinary team incorporates various perspectives to drive towards new therapies, while our external partnerships expand the reach of what’s possible.
WHO WE ARE
The Art of Seeing What is Invisible to Others
We believe we are at the cusp of another transformational era of medicine with the advent of new technologies that allow us to see and understand cells in completely new ways, most notably single-cell RNA sequencing and machine learning. What sets Celsius apart is how we apply the power of these technologies at scale to observe cellular programs in actual human disease.
Our SCOPE platform enables us to identify new targets and patient subsets in complex, multifactorial diseases. The ability to “see” the behavior of human cells in disease progression means that we can design more targeted discovery and development programs and build an extensive pipeline of drugs.
Board of Directors
Partner, Third Rock Ventures
Suzanne Jung Angell
Director of Therapeutic Research, Casdin Capital
Tariq Kassum, M.D.
Chief Executive Officer
Christoph Lengauer, Ph.D.
René Russo, Pharm.D.
CEO, Xilio Therapeutics
Andrea van Elsas, Ph.D.
Venture Partner, Third Rock Ventures
Jeffrey Bluestone, Ph.D.
President and CEO, Sonoma Biotherapeutics
Vijay Kuchroo, DVM, Ph.D.
Samuel L. Wasserstrom Professor of Neurology, Harvard Medical School
Christoph Lengauer, Ph.D.
Aviv Regev, Ph.D.
Head of Genentech Research & Early Development (gRED)
Ramnik Xavier, M.D., Ph.D.
Core Institute Member, Broad Institute, and Kurt Isselbacher Professor of Medicine, Harvard Medical School
Scientific Advisory Board
Maria T. Abreu, M.D.
Director, Crohn’s and Colitis Center, Professor of Medicine, and Professor of Microbiology and Immunology, University of Miami, Miller School of Medicine
Richard Flavell, Ph.D., FRS
Sterling Professor of Immunobiology, Yale University School of Medicine
Peter Kharchenko, Ph.D.
Principal Scientist, Altos Labs San Diego Institute; Gilbert S. Omenn Associate Professor of Biomedical Informatics, Harvard Medical School
Florian Rieder, M.D.
Vice Chair, Co-Director IBD Section, Director IBD Research, Director IBD Advanced Fellowship, Cleveland Clinic
Ton N. Schumacher, Ph.D.
Senior Member, The Netherlands Cancer Institute
Nir Yosef, Ph.D.
Associate Professor, Department of Systems Immunology, Weizmann Institute; Associate Professor, Department of Electrical Engineering and Computer Science, UC Berkeley